PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients

SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025

Read more at globenewswire.com